Home/Filings/4/0001209191-23-028527
4//SEC Filing

Foresite Capital Fund IV, L.P. 4

Accession 0001209191-23-028527

CIK 0001797768other

Filed

May 9, 8:00 PM ET

Accepted

May 10, 5:42 PM ET

Size

18.4 KB

Accession

0001209191-23-028527

Insider Transaction Report

Form 4
Period: 2023-05-08
Transactions
  • Purchase

    Common Stock

    2023-05-08$2.80/sh+1,550,956$4,342,6773,525,957 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2023-05-08$2.80/sh+229,044$641,323520,711 total(indirect: See Footnote)
Holdings
  • Common Stock

    (indirect: See Footnote)
    9,671,643
Footnotes (3)
  • [F1]The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
  • [F2]The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
  • [F3]The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum, in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Issuer

Kinnate Biopharma Inc.

CIK 0001797768

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001704131

Filing Metadata

Form type
4
Filed
May 9, 8:00 PM ET
Accepted
May 10, 5:42 PM ET
Size
18.4 KB